December 27, 2014 7:33 PM ET

Capital Markets

Company Overview of Auven Therapeutics Management L.L.L.P

Company Overview

Auven Therapeutics Management L.L.L.P formerly known as Celtic Therapeutics Holdings L.P. is a private equity firm specializing in acquiring and investing in proprietary therapeutic product candidates (small-molecules and biologics), drug development, and complementary technologies. The firm also invests in developing mid-stage pharmaceutical programs. It acquires ownership of clinical-stage therapeutic assets and potential new products, primarily mid-stage development programs, with all their associated intellectual property and proprietary preclinical and clinical data. Auven Therapeutics Management L.L.L.P was founded in 2007 and is based in Saint Thomas, Virgin Islands, with additional o...

6501 Redhook Plaza

Suite 201

Saint Thomas, VI 00802

United States

Founded in 2007

Phone:

340-779-6908

Fax:

340-714-5192

Key Executives for Auven Therapeutics Management L.L.L.P

Co-Founder and Co-Managing General Partner
Age: 60
Co-Founder and Co-Managing General Partner
Age: 66
Managing Director
Age: 48
Partner and Managing Director of Investments and Business Development
Age: 60
Partner of European Origination and Managing Director of Investments and Business Development
Compensation as of Fiscal Year 2014.

Auven Therapeutics Management L.L.L.P Key Developments

BELLUS And Auven Engage Advisor For Drug Sale

BELLUS Health Inc. (TSX:BLU) and Auven Therapeutics Management L.L.L.P have engaged Lazard Ltd. (NYSE:LAZ) as financial advisor to explore the sale of KIACTA(TM). Auven and BELLUS Health amended the asset purchase and license agreement related to KIACTA(TM) to facilitate a potential sale of KIACTA(TM). Stephen Evans-Freke, co-founder and Managing General Partner of Auven Therapeutics, said, "We have received a number of indications of strong interest from prospective buyers keen to have sufficient lead time to prepare for a global launch. Therefore, it makes sense to facilitate this step by modifying our agreement with BELLUS Health, and to appoint an advisor to explore sale options."

Auven Therapeutics, Bellus Health Inc. Announce Agreement with Mount Sinai for Sarcoidosis Drug Development

Auven Therapeutics and BELLUS Health Inc. reported that Auven has entered into a license agreement with the Icahn School of Medicine at Mount Sinai in New York, under which Auven obtains rights to develop KIACTA (eprodisate) as a treatment for chronic sarcoidosis. Auven intends to conduct a Phase II (proof-of-concept) clinical trial to evaluate KIACTA's effectiveness and safety to treat certain medical manifestations of sarcoidosis. Auven expects to finalize a study protocol by mid-year and anticipates that the trial will start dosing patients in the fourth quarter of 2014. The Phase II trial is expected to be completed within approximately 18 months of the time the first patient is enrolled.

Similar Private Companies By Industry

Company Name Region
Buckhead Financial Corporation United States
Howell Capital United States
Han Logistics, Inc. United States
Gauntlet Commercial Real Estate Capital, LLC United States
Dimirak Securities Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Auven Therapeutics Management L.L.L.P, please visit www.auventx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.